[HTML][HTML] First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study …
G Yamamoto, H Asahina, O Honjo, T Sumi… - Scientific reports, 2021 - nature.com
Osimertinib is a standard of care therapy for previously untreated epidermal growth factor
receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding …
receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding …
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study …
G Yamamoto, H Asahina, O Honjo, T Sumi… - Scientific …, 2021 - europepmc.org
Osimertinib is a standard of care therapy for previously untreated epidermal growth factor
receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding …
receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding …
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study …
G Yamamoto, H Asahina, O Honjo, T Sumi… - Scientific Reports, 2021 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Osimertinib is a standard of care therapy for
previously untreated epidermal growth factor receptor mutation-positive non-small cell lung …
previously untreated epidermal growth factor receptor mutation-positive non-small cell lung …
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study …
G Yamamoto, H Asahina, O Honjo, T Sumi… - Scientific …, 2021 - ui.adsabs.harvard.edu
Osimertinib is a standard of care therapy for previously untreated epidermal growth factor
receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding …
receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding …
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study …
G Yamamoto, H Asahina, O Honjo, T Sumi… - Scientific …, 2021 - eprints.lib.hokudai.ac.jp
Osimertinib is a standard of care therapy for previously untreated epidermal growth factor
receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding …
receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding …
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study …
G Yamamoto, H Asahina, O Honjo, T Sumi… - Scientific …, 2021 - pubmed.ncbi.nlm.nih.gov
Osimertinib is a standard of care therapy for previously untreated epidermal growth factor
receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding …
receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding …
[HTML][HTML] First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study …
G Yamamoto, H Asahina, O Honjo, T Sumi… - Scientific …, 2021 - ncbi.nlm.nih.gov
Osimertinib is a standard of care therapy for previously untreated epidermal growth factor
receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding …
receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding …
First-line osimertinib in elderly patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer: a retrospective multicenter study …
G Yamamoto, H Asahina, O Honjo, T Sumi… - Scientific …, 2021 - search.ebscohost.com
Osimertinib is a standard of care therapy for previously untreated epidermal growth factor
receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding …
receptor mutation-positive non-small cell lung cancer. However, limited data exist regarding …